General MedicationsORALStandard
ELIQUIS SPRINKLE
APIXABAN
Standard Dose
0.15MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview ELIQUIS SPRINKLE is listed in Drugs@FDA under application 220073 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient APIXABAN Form and strength FOR SUSPENSION;ORAL - 0.15MG Sponsor BRISTOL Submission history Latest submission status date: 2025-04-17 00:00:00.
Structured Monograph
Clinical summary
Approval overview ELIQUIS SPRINKLE is listed in Drugs@FDA under application 220073 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient APIXABAN Form and strength FOR SUSPENSION;ORAL - 0.15MG Sponsor BRISTOL Submission history Latest submission status date: 2025-04-17 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.